Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
TriNetX, Inc., Cambridge, Massachusetts, United States of America.
PLoS Med. 2020 Sep 10;17(9):e1003321. doi: 10.1371/journal.pmed.1003321. eCollection 2020 Sep.
At the beginning of June 2020, there were nearly 7 million reported cases of coronavirus disease 2019 (COVID-19) worldwide and over 400,000 deaths in people with COVID-19. The objective of this study was to determine associations between comorbidities listed in the Charlson comorbidity index and mortality among patients in the United States with COVID-19.
A retrospective cohort study of adults with COVID-19 from 24 healthcare organizations in the US was conducted. The study included adults aged 18-90 years with COVID-19 coded in their electronic medical records between January 20, 2020, and May 26, 2020. Results were also stratified by age groups (<50 years, 50-69 years, or 70-90 years). A total of 31,461 patients were included. Median age was 50 years (interquartile range [IQR], 35-63) and 54.5% (n = 17,155) were female. The most common comorbidities listed in the Charlson comorbidity index were chronic pulmonary disease (17.5%, n = 5,513) and diabetes mellitus (15.0%, n = 4,710). Multivariate logistic regression analyses showed older age (odds ratio [OR] per year 1.06; 95% confidence interval [CI] 1.06-1.07; p < 0.001), male sex (OR 1.75; 95% CI 1.55-1.98; p < 0.001), being black or African American compared to white (OR 1.50; 95% CI 1.31-1.71; p < 0.001), myocardial infarction (OR 1.97; 95% CI 1.64-2.35; p < 0.001), congestive heart failure (OR 1.42; 95% CI 1.21-1.67; p < 0.001), dementia (OR 1.29; 95% CI 1.07-1.56; p = 0.008), chronic pulmonary disease (OR 1.24; 95% CI 1.08-1.43; p = 0.003), mild liver disease (OR 1.26; 95% CI 1.00-1.59; p = 0.046), moderate/severe liver disease (OR 2.62; 95% CI 1.53-4.47; p < 0.001), renal disease (OR 2.13; 95% CI 1.84-2.46; p < 0.001), and metastatic solid tumor (OR 1.70; 95% CI 1.19-2.43; p = 0.004) were associated with higher odds of mortality with COVID-19. Older age, male sex, and being black or African American (compared to being white) remained significantly associated with higher odds of death in age-stratified analyses. There were differences in which comorbidities were significantly associated with mortality between age groups. Limitations include that the data were collected from the healthcare organization electronic medical record databases and some comorbidities may be underreported and ethnicity was unknown for 24% of participants. Deaths during an inpatient or outpatient visit at the participating healthcare organizations were recorded; however, deaths occurring outside of the hospital setting are not well captured.
Identifying patient characteristics and conditions associated with mortality with COVID-19 is important for hypothesis generating for clinical trials and to develop targeted intervention strategies.
2020 年 6 月初,全球报告的 2019 冠状病毒病(COVID-19)病例接近 700 万例,COVID-19 患者死亡人数超过 40 万。本研究的目的是确定 Charlson 合并症指数中列出的合并症与美国 COVID-19 患者死亡率之间的关系。
这是一项在美国 24 家医疗机构进行的 COVID-19 成年患者的回顾性队列研究。研究包括 2020 年 1 月 20 日至 2020 年 5 月 26 日期间其电子病历中编码有 COVID-19 的年龄在 18-90 岁的成年人。结果还按年龄组(<50 岁、50-69 岁或 70-90 岁)进行分层。共纳入 31461 例患者。中位年龄为 50 岁(四分位间距[IQR],35-63),54.5%(n=17155)为女性。Charlson 合并症指数中最常见的合并症是慢性肺部疾病(17.5%,n=5513)和糖尿病(15.0%,n=4710)。多变量逻辑回归分析显示,年龄较大(每年的优势比[OR]为 1.06;95%置信区间[CI]为 1.06-1.07;p<0.001)、男性(OR 1.75;95%CI 1.55-1.98;p<0.001)、与白人相比为黑人或非裔美国人(OR 1.50;95%CI 1.31-1.71;p<0.001)、心肌梗死(OR 1.97;95%CI 1.64-2.35;p<0.001)、充血性心力衰竭(OR 1.42;95%CI 1.21-1.67;p<0.001)、痴呆症(OR 1.29;95%CI 1.07-1.56;p=0.008)、慢性肺部疾病(OR 1.24;95%CI 1.08-1.43;p=0.003)、轻度肝脏疾病(OR 1.26;95%CI 1.00-1.59;p=0.046)、中度/重度肝脏疾病(OR 2.62;95%CI 1.53-4.47;p<0.001)、肾脏疾病(OR 2.13;95%CI 1.84-2.46;p<0.001)和转移性实体瘤(OR 1.70;95%CI 1.19-2.43;p=0.004)与 COVID-19 死亡率较高相关。在年龄分层分析中,年龄较大、男性和黑人或非裔美国人(与白人相比)与死亡风险增加仍然显著相关。在不同年龄组之间,确定与死亡率显著相关的合并症存在差异。局限性包括数据来自医疗机构的电子病历数据库,一些合并症可能报告不足,并且 24%的参与者的种族不详。记录了参加医疗机构的住院或门诊就诊期间的死亡情况;但是,医院外的死亡情况无法很好地捕捉。
确定与 COVID-19 死亡率相关的患者特征和疾病对于临床试验的假设生成和制定有针对性的干预策略很重要。